Thesis as of Oct 21, 2026
INMune Bio is a clinical-stage biopharmaceutical company developing CORDStrom, a cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disease, and that therapy is not yet approved anywhere, with a UK conditional marketing authorization application in preparation.
CORDStrom, a cord-derived stromal cell therapy for recessive dystrophic epidermolysis bullosa, has received written MHRA alignment across all pre-MAA questions, putting a 2026 UK conditional marketing authorization on track. The thesis turns on whether conditional approval arrives before cash runs out, given $18M remaining at a $6.5M quarterly burn. XPro1595 adds optionality via an FDA-aligned Phase 2b/3 design but requires a strategic partner and has shown only imaging biomarker signals.
Going-concern disclosed; $18M cash, $6.5M/qtr burn
Current Thesis Drivers
What could change the thesis?
Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.
Thesis log
Tracked in real time as it happened — not reconstructed after the fact
Key value driver
The most decisive event ahead
Bull and bear case
Both sides of the Thesis, argued
Pipeline
8 programs · 14 catalysts